Low-dose CT screening for lung cancer following Lung-RADS criteria may reduce false positives, but it also decreases sensitivity.
Lung cancer screening with low-dose computed tomography may substantially reduce the false-positive result rate, but sensitivity is also decreased, according to a study published in the Annals of Internal Medicine.
Researchers from several states performed a study to assess the retrospective application of the Lung-RADS criteria to the National Lung Screening Trial (NLST).
The study included 26,722 participants (aged 55 to 74) who had undergone three annual low-dose computed tomography (LDCT) scans. The subjects had at least a 30–pack-year history of smoking, and were current smokers or had quit within the past 15 years.
The results showed that 26,455 participants received a baseline screen and 48,671 screenings were performed after baseline.
The researchers concluded that while Lung-RADS may substantially reduce the false-positive result rate, sensitivity is also decreased. They suggest that the effect of using Lung-RADS criteria in clinical practice must be carefully studied.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.